Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
Advances in the treatment of heart failure may require manipulation of neurohumoral responses to cardiac impairment in addition to the established strategy of angiotensin-converting enzyme (ACE) inhibition. Importantly, since new treatments are likely to be used in conjunction with ACE inhibition therapy, the effects of the combination of agents need to be assessed. Adrenomedullin (ADM) is a peptide with potent vasodilator and natriuretic actions. ADM and an ACE inhibitor (captopril) were administered for 3 h both separately and together in eight sheep with heart failure. Both ADM and captopril alone reduced arterial pressure, left atrial pressure (greater with captopril) and peripheral resistance, and increased cardiac output (greater with ADM). Compared with either treatment separately, combined ADM+captopril produced directionally similar but significantly greater changes in all haemodynamic variables (particularly falls in blood pressure). ADM increased renal sodium and creatinine excretion and creatinine clearance, and maintained urine output. Captopril and ADM+captopril reduced creatinine excretion and creatinine clearance, while urine volume and sodium excretion were not significantly altered. Plasma renin activity rose with all active treatments, whereas angiotensin II levels rose during ADM, but fell during captopril and ADM+captopril. Aldosterone was reduced by all active treatments. ADM+captopril reduced plasma noradrenaline (norepinephrine). In conclusion, short-term co-treatment with ADM and an ACE inhibitor produced significantly greater decreases in ventricular filling pressures and cardiac afterload, and increases in cardiac output, compared with either treatment alone. Despite the greater falls in blood pressure (and presumably renal perfusion pressure), renal function was maintained at a level similar to that observed with captopril alone.
Rademaker
Miriam T
MT
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, P.O. Box 4345, New Zealand. miriam.rademaker@chmeds.ac.nz
Charles
Chris J
CJ
Cooper
Garth J S
GJ
Coy
David H
DH
Espiner
Eric A
EA
Lewis
Lynley K
LK
Nicholls
M Gary
MG
Richards
A Mark
AM
D053607:Adrenomedullin; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002216:Captopril / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D006439:Hemodynamics / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D010455:Peptides / Q000627:therapeutic use*; D011188:Potassium / Q000652:urine; D012756:Sheep; D012964:Sodium / Q000652:urine; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D010455:Peptides; D014665:Vasodilator Agents; D053607:Adrenomedullin; D002216:Captopril; D012964:Sodium; D003404:Creatinine; D011188:Potassium